Steven Carl George

Steven Carl George

Auto-generated profile, based on publicly available information

Steven Carl George

Department of Biomedical Engineering, University of California, Davis, Davis, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2018 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
VSVenktesh S. Shirure
Venktesh S. Shirure
YBYe Bi
Ye Bi
MCMatthew B. Curtis
Matthew B. Curtis
ALAndrew Lezia
Andrew Lezia
MGMadeleine M. Goedegebuure
Madeleine M. Goedegebuure
SGSteven C. George
Steven C. George
Most cancer treatment strategies target cell proliferation, angiogenesis, migration, and intravasation of tumor cells in an attempt to limit tumor growth and metastasis. An in vitro platform to assess tumor progression and drug sensitivity could provide avenues to enhance our understanding of tumor metastasis as well as precision medicine. We present a microfluidic platform that mimics biological mass transport near the arterial end of a capillary in the tumor microenvironment. A central feature is a quiescent perfused 3D microvascular network created prior to loading tumor cells or patient-derived tumor organoids in an adjacent compartment. The physiological delivery of nutrients and/or drugs to the tumor then occurs through the vascular network. We demonstrate the culture, growth, and treatment of tumor cell lines and patient-derived breast cancer organoids. The platform provides the opportunity to simultaneously and dynamically observe hallmark features of tumor progression including cell proliferation, angiogenesis, cell migration, and tumor cell intravasation. Additionally, primary breast tumor organoids are viable in the device for several weeks and induce robust sprouting angiogenesis. Finally, we demonstrate the feasibility of our platform for drug discovery and personalized medicine by analyzing the response to chemo- and anti-angiogenic therapy. Precision medicine-based cancer treatments can only be realized if individual tumors can be rapidly assessed for therapeutic sensitivity in a clinically relevant timeframe (≲14 days). Our platform indicates that this goal can be achieved and provides compelling opportunities to advance precision medicine for cancer.

28 October 2024 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
RCRandy Carney
Randy Carney
RMRachel R. Mizenko
Rachel R. Mizenko
BBBatuhan T. Bozkurt
Batuhan T. Bozkurt
NLNeona Lowe
Neona Lowe
THTanner Henson
Tanner Henson
SGSteven C. George
Steven C. George

13 July 2021 in Annual Review of Biomedical Engineering
Verified
Journal Article
Open access
VSVenktesh S. Shirure
Venktesh S. Shirure
CHChristopher C.W. Hughes
Christopher C.W. Hughes
SGSteven C. George
Steven C. George
Recreating human organ–level function in vitro is a rapidly evolving field that integrates tissue engineering, stem cell biology, and microfluidic technology to produce 3D organoids. A critical component of all organs is the vasculature. Herein, we discuss general strategies to create vascularized organoids, including common source materials, and survey previous work using vascularized organoids to recreate specific organ functions and simulate tumor progression. Vascularization is not only an essential component of individual organ function but also responsible for coupling the fate of all organs and their functions. While some success in coupling two or more organs together on a single platform has been demonstrated, we argue that the future of vascularized organoid technology lies in creating organoid systems complete with tissue-specific microvasculature and in coupling multiple organs through a dynamic vascular network to create systems that can respond to changing physiological conditions.

1 January 2022 in Biomaterials
Verified
Journal Article
Closed access
DGDrew E. Glaser
Drew E. Glaser
MCMatthew B. Curtis
Matthew B. Curtis
PSPeter A. Sariano
Peter A. Sariano
ZRZachary A. Rollins
Zachary A. Rollins
BSBhupinder S. Shergill
Bhupinder S. Shergill
SGSteven C. George
Steven C. George

1 August 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
NPNuala Del Piccolo
Nuala Del Piccolo
VSVenktesh S. Shirure
Venktesh S. Shirure
YBYe Bi
Ye Bi
SGS. Peter Goedegebuure
S. Peter Goedegebuure
SGSepideh Gholami
Sepideh Gholami
SGSteven C. George
Steven C. George
Every year, cancer claims millions of lives around the globe. Unfortunately, model systems that accurately mimic human oncology - a requirement for the development of more effective therapies for these patients - remain elusive. Tumor development is an organ-specific process that involves modification of existing tissue features, recruitment of other cell types, and eventual metastasis to distant organs. Recently, tissue engineered microfluidic devices have emerged as a powerful in vitro tool to model human physiology and pathology with organ-specificity. These organ-on-chip platforms consist of cells cultured in 3D hydrogels and offer precise control over geometry, biological components, and physiochemical properties. Here, we review progress towards organ-specific microfluidic models of the primary and metastatic tumor microenvironments. Despite the field's infancy, these tumor-on-chip models have enabled discoveries about cancer immunobiology and response to therapy. Future work should focus on the development of autologous or multi-organ systems and inclusion of the immune system.

3 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MSMary Kathryn Sewell-Loftin
Mary Kathryn Sewell-Loftin
SBSamantha Van Hove Bayer
Samantha Van Hove Bayer
ECElizabeth Crist
Elizabeth Crist
THTaylor Hughes
Taylor Hughes
SJSofia M. Joison
Sofia M. Joison
SGSteven C. George
Steven C. George
The role of cancer-associated fibroblasts (CAFs) as regulators of tumor progression, specifically vascular growth, has only recently been described. CAFs are thought to be more mechanically active but how this trait may alter the tumor microenvironment is poorly understood. We hypothesized that enhanced mechanical activity of CAFs, as regulated by the Rho/ROCK pathway, contributes to increased blood vessel growth. Using a 3D in vitro tissue model of vasculogenesis, we observed increased vascularization in the presence of breast cancer CAFs compared to normal breast fibroblasts. Further studies indicated this phenomenon was not simply a result of enhanced soluble signaling factors, including vascular endothelial growth factor (VEGF), and that CAFs generated significantly larger deformations in 3D gels compared to normal fibroblasts. Inhibition of the mechanotransductive pathways abrogated the ability of CAFs to deform the matrix and suppressed vascularization. Finally, utilizing magnetic microbeads to mechanically stimulate mechanically-inhibited CAFs showed partial rescue of vascularization. Our studies demonstrate enhanced mechanical activity of CAFs may play a crucial and previously unappreciated role in the formation of tumor-associated vasculature which could possibly offer potential novel targets in future anti-cancer therapies.